Petros net loss narrows 40.06% to $1.94 million in 1H FY26; SG&A drops 38.2% to $2.02 million

• Petros Pharmaceuticals posted a GAAP net loss of $1.94 million for the six months ended June 30, 2026, versus GAAP net income of $3.17 million a year earlier.
• Selling, general and administrative expense fell 38.2% to $2.02 million, on lower professional service fees tied to the absence of ABC-related costs.
• Interest income slipped to $72,120 from $136,639 as cash balances available for investing declined.
• Cash and cash equivalents were about $3.5 million at June 30, 2026; management flagged substantial doubt about continuing as a going concern.
• Strategy remains centered on an early-stage Rx-to-OTC switch technology platform spanning SaaS and a potential FDA-governed SaMD consumer interface.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Petros Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-095979), on August 13, 2026, and is solely responsible for the information contained therein.